Search...
Hepion Pharmaceuticals Appoints Kaouthar Lbiati As Interim CEO
I'm PortAI, I can summarize articles.
Hepion Pharmaceuticals has appointed Kaouthar Lbiati as interim CEO effective June 16, following the retirement of John Brancaccio for personal reasons. Lbiati, a board member since June 2022, brings over 15 years of leadership experience in biotech and large pharmaceutical companies.
Hepion Pharmaceuticals, Inc. (HEPA) said on Monday that it has appointed Kaouthar Lbiati as interim Chief Executive Officer with effect from June 16 after John Brancaccio decided to retire for personal reasons.
Lbiati has been serving as a member of Hepion's Board since June 2022 and has over 15 years of leadership experience in both biotech and large pharmaceutical companies.
For comments and feedback contact: editorial@rttnews.com
Business News
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments